Kareus Therapeutics Enters Strategic Drug Development Alliance With Quintiles

LA CHAUX-DE-FONDS, Switzerland, June 13, 2011 /PRNewswire/ --


- Alliance Combines Innovative Drug Discovery With World-Class Development Expertise and Global Infrastructure to Expedite Clinical Proof-of-Relevance in Two Programs

Kareus Therapeutics SA ("Kareus" or the "Company"), the company focused on the development of novel therapeutics to address high unmet medical need, today announced a broad strategic alliance with Quintiles to progress the development of two of Kareus' pre-clinical programs through clinical trials.

Under the terms of the alliance, Quintiles will make an investment in Kareus in the USD$ seven figure range, apportioned between an equity investment and access to clinical service on a shared-risk basis. Following the investment by Quintiles, Kareus plans to submit an investigational new drug (IND) application for KU-046, a first-in-class new chemical entity discovered by Kareus for the treatment of Alzheimer's disease. Kareus has also identified a lead series of molecules demonstrating potent, long-lasting insulin sensitisation with a broad therapeutic window for the treatment of Type-2 diabetes and will select a clinical candidate for development later in 2011. Quintiles will conduct Phase I proof-of-relevance clinical trials for both KU-046 and the chosen diabetes candidate.

Tom Perkins, Senior Vice President of Corporate Development for Quintiles said: "This agreement is an example of how leading biotechnology companies are building partnerships that extend beyond the traditional licensing model to manage risk, increase productivity, and increase value to stakeholders. We are pleased that Kareus has chosen to leverage Quintiles' suite of comprehensive services, including our new Phase I research unit in Hyderabad, India."

Patrick Doyle of Kareus Therapeutics said: "We are delighted to have signed this alliance with Quintiles, a leading global provider of clinical services. With Quintiles as our partner, Kareus is now ideally placed to accelerate the development of our novel drug pipeline and advance the first product candidates generated by our innovative discovery platform, KARLECT, into clinical studies."

Kareus has developed a pipeline of novel molecules targeting diseases of the central nervous system based on its proprietary KARLECT chemistry and drug discovery platform which targets molecular and gene expression pathways. KU-046, discovered using the KARLECT platform, targets pathways upstream from the increased abeta peptide production found in Alzheimer's disease and has demonstrated significant improvement in cognition in a number of pre-clinical models. Kareus will also seek to develop novel small molecule candidates in metabolic diseases, including diabetes, and inflammation. In addition, the leadership team of Kareus has an extensive background in cardiovascular disease and has applied this know-how to the development of 505(b)(2) filings for lipid lowering and cardiovascular disease.

About Kareus Therapeutics SA

Kareus Therapeutics SA is a private biotechnology company focused on the development of novel therapeutics to address high unmet medical need. Kareus was founded on the scientific expertise of Dr Uday Saxena and is organised in a virtual manner, led by a highly experienced team comprising Dr.'s Uday Saxena (R&D strategy), Ish Khanna (chemistry & pre-clinical), Ram Pillarisetti (research & pre-clinical), Akella Venkateswarlu (IP & science) and Patrick Doyle (business & corporate). Kareus employs three approaches to drug discovery and development: i) KARLECT, a unique enabling chemistry platform that combines currently marketed drugs and GRAS molecules to produce new chemical entities, which has been applied to Alzheimer's disease; ii) novel small molecule drug discovery in metabolic diseases & inflammation; and iii) 505(b)(2) approaches to lipid lowering and cardiovascular disease, leveraging its extensive global networks with contract research organizations, academic laboratories and biotechnology companies. For further information, please visit http://www.kareustherapeutics.com

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps bio pharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit http://www.quintiles.com

    
    For more information about Kareus Therapeutics, please contact:

    Kareus Therapeutics
    Patrick Doyle
    T: +44(0)7871-309-056
    E: [email protected]

    M:Communications
    Emma Thompson
    T: +44(0)20-7920-2330
    E: [email protected]

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.